SHANGHAI, July 27, 2026 /PRNewswire/ -- AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), today announced that construction of its new R&D building has officially broken ground at the Shanghai Fengxian site. The project marks a pivotal infrastructure step in strengthening AsymBio's biologics CDMO capabilities and reinforcing the Fengxian site's role as a core development-and-manufacturing hub.Construction began in May 2026, with full completion and official commissioning slated for the second half of 2027. The eight-story building will occupy approximately 2,500 square meters of land, provide nearly 20,000 square meters of gross floor area, and be constructed in full compliance with green and low-carbon construction standards. The facility will support cell line development, upstream and downstream process development, conjugation process development, drug product development, and comprehensive analytical development services.Located within AsymBio's Fengxian site, adjacent to the clinical and commercial manufacturing facilities for antibodies and antibody-drug conjugates (ADCs), the building will serve as a dedicated R&D hub. Once operational, it will work in close alignment with the site's production lines to streamline scale-up and commercial manufacturing while shortening overall project timelines.The Fengxian R&D building will also provide the core physical carrier for the AccPCC (Accelerated PCC platform), an integrated R&D acceleration platform designed to shorten the development timeline from lead to preclinical candidate (PCC) selection. Built around an end-to-end, AI-enabled workflow, AccPCC connects early R&D and CMC with nonclinical evaluation and early clinical translation. The platform delivers full-spectrum technical support spanning lead optimization, developability assessment, and early-stage customized CMC strategy for global biotech partners.Rui Yang, CEO of AsymBio, commented, ＂Effective biologics development requires earlier engagement, integrated scientific and CMC decision-making, and manufacturability considerations from the outset. By leveraging cross-site R&D resources across the entire Asymchem Group, AccPCC is designed to improve development efficiency, shorten the path to PCC selection and accelerate science-to-clinic translation. The Fengxian R&D building will be a key enabler of closer integration between early development, scale-up and manufacturing, helping clients reduce handoffs and manage complex programs with greater clarity, continuity and confidence.＂About AsymBioAsymBio, a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), focuses exclusively on biopharmaceutical CDMO services. Backed by Asymchem Group's 30 years of experience and global operations, AsymBio delivers one-stop CDMO services from early-stage and process development to toxicology, clinical, and commercial-scale manufacturing. Building on deep ADC experience, AsymBio is expanding into NDCs, including RDCs, AOCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for antibody therapeutics, including monoclonal, bispecific, and multispecific antibodies, and protein-based therapeutics, including fusion proteins and recombinant proteins.For more information, visit www.asymbio.com or follow us on LinkedIn.Business inquiries: MKT@asymchem.com.cnCompliance NotesForward-Looking Statement Disclaimer: This press release contains forward-looking statements regarding future events and expectations. Actual results may differ materially due to various factors. AsymBio undertakes no obligation to update these statements.Non-Solicitation Statement: This announcement is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities.

We were pleased to host a Technical Salon in South Korea, bringing together industry experts and partners to exchange insights on ADCs and next-generation biotherapeutics. The event featured discussions spanning innovative ADC technologies, CMC strategies, bispecific ADCs, pharmacodynamic evaluation, and clinical development.As part of the Asymchem Group, AsymBio, together with our sister companies Yugen Medtech and Clin-nov, combines complementary expertise to deliver one-stop, end-to-end solutions for global ADC innovators. With integrated capabilities across non-clinical CRO, clinical CRO, and ADC CMC services, we support partners throughout the entire development journey—from early-stage research to commercial manufacturing.A sincere thank you to all of our speakers, guests, and attendees for making this event a success, and special thanks to our local partner, Double Eight Partners, for their outstanding collaboration and support.We look forward to continuing to build strong partnerships across Korea's biopharmaceutical community.

Refreshing Our Look. Reinforcing Our Commitment.Today, AsymBio officially unveils our new logo and refreshed brand identity. As a global CDMO specializing in antibodies, ADCs, and advanced biotherapeutics, our refreshed visual identity reflects our continued growth, global perspective, and closer alignment with the Asymchem brand.While our look has evolved, our commitment remains the same. We continue to deliver reliable, high-quality development and manufacturing solutions, helping our partners accelerate innovation through trusted collaboration and scientific excellence. We look forward to continuing this journey together with our customers and partners around the world.

SHANGHAI, May 27, 2026 (GLOBE NEWSWIRE) -- AsymBio, a biologics-focused CDMO and subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), today showcased its Conjugation Toolbox, a technology platform designed to support customized and scalable process development for next-generation bioconjugates.As antibody-drug conjugates (ADCs) and other bioconjugates evolve toward more complex formats, conjugation process development has become increasingly important to product quality, manufacturability, and CMC readiness. AsymBio’s Conjugation Toolbox provides a flexible framework for developing and optimizing fit-for-purpose conjugation process, with tailored strategies aligned with each candidate’s molecular format, linker-payload design, and development objectives.The Conjugation Toolbox supports both random and site-specific conjugation technologies, including cysteine- and lysine-based approaches, as well as engineered cysteine conjugation, interchain cysteine bridging, enzymatic conjugation, and glyco-remodeling conjugation. Across these approaches, AsymBio has extensive hands-on experience with diverse linker-payload combinations and ADC programs across a range of average Drug-to-Antibody Ratio (DAR) values, including, but not limited to, DAR 2, DAR 4, DAR 8, and higher-DAR formats.Specifically, within site-specific conjugation, AsymBio has established CMC development expertise with microbial transglutaminase (mTG)- and sortase-based platforms for enzymatic conjugation. For glyco-remodeling conjugation, AsymBio’s CMC experience covers multiple established technologies, including GlycoConnect™ (Synaffix, now part of Lonza), GlycoT™ (GlycoT Therapeutics), DisacLink™ (GlycanLink), and iGDC™ (GeneQuantum).Previously shortlisted in the “Best ADC Platform Technology” category at the 2025 World ADC Awards, the Conjugation Toolbox is designed to enable high DAR homogeneity and consistent process performance across development stages for emerging formats such as bispecific and dual-payload ADCs. It also incorporates integrated purification process development and free drug removal strategies to address process- and product-related impurities in complex bioconjugate programs.For Investigational New Drug (IND)-enabling programs, conjugation process development can typically be completed in as little as two to three months. In addition, AsymBio conducts 20–50 g process lock runs and 2–5 g use tests with manufacturing-grade materials to confirm key parameters prior to the start of manufacturing. Under strict environmental, health, and safety (EHS) controls for Occupational Exposure Band 5 (OEB5) materials, the platform facilitates efficient technology transfer, scale-up, and GMP manufacturing, helping clients maintain consistent product quality throughout the product lifecycle.About AsymBioAsymBio, a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), focuses exclusively on biopharmaceutical CDMO services. Backed by Asymchem Group’s 30 years of experience and global operations, AsymBio delivers one-stop CDMO services from early-stage and process development to clinical, toxicology, and commercial-scale manufacturing. Building on deep ADC experience, AsymBio is expanding into NDCs, including RDCs, AOCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for antibody therapeutics (monoclonal, bispecific, and multispecific antibodies) and protein-based therapeutics (fusion proteins, recombinant proteins).For more information, visit www.asymbio.com or follow us on LinkedIn.Business inquiries: MKT@asymchem.com.cnCompliance NotesForward-Looking Statement Disclaimer: This press release contains forward-looking statements regarding future events and expectations. Actual results may differ materially due to various factors. AsymBio undertakes no obligation to update these statements.Non-Solicitation Statement: This announcement is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities.

AsymBio team has wrapped up the highly productive 22nd Annual PEGS Boston Summit! This year’s event was an incredible platform for deep industry dialogue and meaningful collaboration. We engaged in focused discussions with partners across biotech and pharma, exchanging insights on next-gen antibodies, bioconjugates, and advancing multispecific therapies toward the clinic. Thank you to all partners, collaborators, and organizers for a fantastic summit—we look forward to advancing these dialogues and exploring future synergies.

It was a great pleasure connecting with industry partners and showcasing our integrated CDMO capabilities for biologics and bioconjugates.A special thank you to everyone who joined our session on quality analysis and management for ADC and antibody biopharmaceuticals. Looking forward to continuing the conversations!

Over the past two days, it was a pleasure connecting with so many partners, innovators, and industry peers across the biologics and bioconjugate community. We truly appreciate the engaging conversations around antibodies, ADCs, and next-generation biotherapeutics.A big thank you to everyone who stopped by Booth #331 to meet with our team. We look forward to continuing the conversations and building new collaborations ahead.See you at the next event!Email: MKT@asymchem.com.cn

SHANGHAI, March 09, 2026 — AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), recently announced that its Fengxian commercial manufacturing site in Shanghai has officially commenced operations. This milestone completes a Shanghai-based “Golden Triangle” footprint comprising the Zhangjiang Center of Biological Technology and Innovation, Jinshan Manufacturing Site, and Fengxian Manufacturing Site. The three locations integrate end-to-end CDMO capabilities from early R&D and process development through clinical pilot-scale production, to commercial manufacturing, advancing client programs from IND to BLA through efficient cross-site coordination.AsymBio’s “Dual Sites + One Center” model provides connected functions and complementary strengths across the biologics lifecycle:• Zhangjiang Center of Biological Technology and Innovation (CBTI): A technology-driven central engine for innovation, focusing on early R&D and process development for antibodies, proteins, novel drug conjugates (NDCs), and other advanced therapies, with forward-looking technology deployment. The Center builds and optimizes technology platforms for cell line development, upstream/downstream process development and optimization, conjugation toolbox development, and analytical method development. It supports concept-to-process translation and enables defined technology transfer pathways for subsequent pilot and commercial manufacturing.• Jinshan Manufacturing Site: A one-stop manufacturing site providing manufacturing services from clinical supply and pilot-scale to commercial production, covering drug substance (DS) and drug product (DP) capabilities for antibodies, protein therapeutics, ADCs, and NDCs. The site supports programs across clinical stages, spanning from R&D to antibody DS/DP and conjugate DS/DP.• Fengxian Manufacturing Site: A newly commissioned intelligent, large-scale, and internationally compliant manufacturing site focused on late-stage development and large-scale commercial supply for antibodies, protein therapeutics, ADCs, and NDCs. It introduces advanced smart manufacturing systems to enable compliant operations and meet global demand for large-scale supply of high-quality biologics.Dual-site GMP manufacturing to flexibly support capacity needs from early pilot to large-scale commercial supply The network is equipped with:• Single-use bioreactors for antibody drug substance: 200 L / 500 L / 2,000 L• Conjugation reactors for conjugate drug substance: 50 L / 100 L / 200 L / 500 L• ORABS fully automated filling line• Multi-specification lyophilization and isolator filling systems: 5 m² / 10 m² / 15 m² / 20 m² lyophilizers, supporting 2R–20R formatsThese capabilities support diverse dosage forms and specifications and strengthen integrated delivery in biologics, enabling customized manufacturing services.Integrating Asymchem’s Payload–Linker Facility to Provide End-to-End, One-Stop Services for Drug ConjugatesAsymBio integrates Asymchem Group resources by linking Shanghai’s conjugation manufacturing with the Group’s Tianjin payload–linker R&D and manufacturing capabilities. The Tianjin site focuses on payload–linker process development and manufacturing while connecting seamlessly with Shanghai's antibody DS, conjugate DS, and DP manufacturing and fill-finish. This end-to-end model enables cross-regional coordination, ensures supply chain stability, and improves both execution efficiency and cross-stage collaboration.With the Fengxian site now in operation, AsymBio’s Shanghai footprint covers the full value chain from early-stage development through commercialization. Through the “Dual Sites + One Center” model and integrated payload–linker capabilities, the company provides global clients with efficient, reliable, and customized development and manufacturing solutions, supporting pipelines from the laboratory to clinical development and commercialization.About AsymBioAsymBio, a subsidiary of Asymchem Group, focuses exclusively on biopharmaceutical CDMO services. With more than 25 years of experience and global operations, the company delivers one-stop CDMO services from early-stage and process development to clinical, toxicology, and commercial-scale manufacturing. Building on deep ADC experience, AsymBio is expanding into NDCs, including RDCs, AOCs, PDCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for antibody therapeutics (monoclonal, bispecific, and multispecific antibodies) and protein-based therapeutics (fusion proteins, recombinant proteins).For more information: visit www.asymbio.com or follow us on LinkedIn.Business inquiries: MKT@asymchem.com.cn

As a dedicated CDMO partner in the bioconjugate space, it was a pleasure connecting with industry peers, innovators, and partners to discuss the evolving landscape of ADC development — from payload–linker strategy to integrated CMC solutions.A special thank you to everyone who joined Dr. Tiejun Li’s session on accelerating next-generation bioconjugate drug development through an integrated platform. We were excited to share our perspectives and exchange insights on advancing complex ADC programs with robust, development-ready processes.If we didn’t get the chance to meet during the event, we’d still love to connect. Let’s continue the conversation on how we can support your next ADC milestone.Email:MKT@asymchem.com.cn

SHANGHAI, February 10, 2026 — AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle. Through its end-to-end service capabilities, the company provides streamlined, integrated workflows for client programs from early development to commercial manufacturing.AsymBio is a technology-driven biopharmaceutical CDMO focused on accelerating innovation and providing integrated development and manufacturing services for clients. Key platforms include:1. AmigoCHO™ Cell Line Development Platform — Supports the development of high-titer, high-quality, and stable clones, including cell pool establishment, expansion, clone selection, and stability analysis.Upstream Process Development Platform — Covers process optimization, process scale-up, and process characterization, supporting workflows from preclinical material preparation and IND/BLA-enabling process development to technology transfer and scale-up. Project timelines can be shortened to as little as 9 weeks.2. Downstream Process Development Platform — Designed to shorten process development timelines while supporting higher product purity, reduced impurities, and improved yield, including chromatography process development, filtration process development, tech transfer and scale-up, and process characterization.3. Conjugation Toolbox — A modular and flexible toolbox that enables rapid development and optimization of diverse conjugation processes across multiple bioconjugate modalities, including ADCs, RDCs, AOCs, APCs, and other emerging conjugates. Supported approaches include cysteine- and lysine-based conjugation, enzymatic methods, engineered cysteine approaches, glyco-remodeling, and interchain cysteine re-bridging. The Conjugation Toolbox was shortlisted in the ＂Best ADC Platform Technology＂ category at the 2025 World ADC Awards.4. IMPACT Drug Product Development Platform — Delivers indication-, molecule-, and phase-accountable drug product development services. Supported dosage forms include high-concentration, lyophilized, liquid, and frozen-liquid presentations, with an emphasis on formulation and process solutions for complex and high-potency biologics.5. Payload-Linker CMC Development Platform — Offers multiple payload and linker options, including payloads (e.g., Auristatin, Maytansine, Camptothecin, Eribulin, PBD dimer, macrocyclic molecular glue, E3 ligase ligand, and others) and linkers (e.g., peptide linkers, PEG linkers, sugar linkers, and others). The platform brings extensive CMC development experience, supporting more than 70 IND and 13 NDA projects.6. Comprehensive Analytical Platform — Capable of efficient analytical method development and in-depth product characterization, covering critical quality attributes (CQAs) across every stage of the product lifecycle, and comprising the Physicochemical Platform, Mass Spectrometry Platform, and Bioassay Platform.AsymBio will continue to invest in R&D and technology development, with a focus on advanced technology platforms and data-enabled manufacturing processes. The company noted that technology underpins pharmaceutical innovation; by integrating advanced scientific approaches with large-scale manufacturing experience, AsymBio works to help address complex challenges in biopharmaceutical development, improve manufacturing efficiency and product quality, and support the reliable commercialization of innovative therapies for global clients.About AsymBioAsymBio, a subsidiary of Asymchem Group, focuses exclusively on biopharmaceutical CDMO services. With more than 25 years of experience and global operations, the company delivers one-stop CDMO services from early-stage and process development to clinical, toxicology, and commercial-scale manufacturing. Building on deep ADC experience, AsymBio is expanding into NDCs, including RDCs, AOCs, PDCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for antibody therapeutics (monoclonal, bispecific, and multispecific antibodies) and protein-based therapeutics (fusion proteins, recombinant proteins).For more information: visit www.asymbio.com or follow us on LinkedIn. Business inquiries: MKT@asymchem.com.cn